Back to Interventions

Substance / Medication

Interferon beta-1b

SNOMED 386903009 UMLS C0244713

Overview

Active Ingredient

interferon beta-1b

RxNorm CUI

72257

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Multiple sclerosis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Calcidiol+ercalcidiol

LOINC 14635-7

secondary

LOINC 2132-9

secondary

LOINC 26464-8

secondary

Research Evidence

Published studies and systematic reviews

Sort:

Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.

Kappos Ludwig, Edan Gilles, Freedman Mark S et al. · J Neurol · 2024

PMID: 38730097RCTFull text (PMC)

Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial.

Alotaibi Faizah, Alharbi Naif Khalaf, Rosen Lindsey B et al. · Influenza Other Respir Viruses · 2023

PMID: 36960162RCTFull text (PMC)

Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.

Khamis Faryal, Al Naabi Hanan, Al Lawati Adil et al. · Int J Infect Dis · 2021

PMID: 33181328RCTFull text (PMC)

Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b.

Ramirez-Ramirez V, Macias-Islas M A, Ortiz G G et al. · Oxid Med Cell Longev · 2013

PMID: 23861993RCTFull text (PMC)

Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis.

Penner Iris-Katharina, Stemper Brigitte, Calabrese Pasquale et al. · Mult Scler · 2012

PMID: 22492127RCTFull text (PMC)

Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.

Pan Feng, Goh Jo Wern, Cutter Gary et al. · Clin Ther · 2012

PMID: 22906738RCT

New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate.

Cadavid D, Cheriyan J, Skurnick J et al. · J Neurol Neurosurg Psychiatry · 2009

PMID: 19687024RCT

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.

Montalban X, Sastre-Garriga J, Tintoré M et al. · Mult Scler · 2009

PMID: 19797261RCT

Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers.

Hilpert Jan, Beekman Johanna M, Schwenke Susanne et al. · J Neuroimmunol · 2008

PMID: 18565596RCT

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.

Kappos Ludwig, Freedman Mark S, Polman Chris H et al. · Lancet · 2007

PMID: 17679016RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Neurology Physician

Psychiatry & Neurology — Neurology

NUCC 2084N0400X

Find a Provider

Health Goals

Goals connected through associated conditions

Manage Autoimmune Risk

Quick Facts

Type: Substance / Medication
Fully Specified Name: Interferon beta-1b (substance)
SNOMED CT: 386903009
UMLS CUI: C0244713
RxNorm CUI: 72257

Clinical Data

This intervention maps to 6 entities in the Ltrl knowledge graph.

1

Conditions

3

Biomarkers

1

Specialists

0

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.